infectious disease
Conditions
Interventions
Three to five days after the start of linezolid administration, blood should be drawn to measure plasma concentrations, and the dose should be changed (either continued at the current dose or reduced)
Sponsors
Gifu Prefectural Tajimi Hospital
Gifu Pharmaceutical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients 18 years of age or older treated with LZD Patients diagnosed with an orthopedic infection between September 1, 2023 and September 31, 2025 Patients with written consent to participate in this study
Exclusion criteria
Exclusion criteria: Patients allergic to LZD Patients with disseminated intravascular coagulation syndrome
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment efficacy (duration of LZD treatment, treatment completion rate, clinical improvement rate of infection) and incidence of adverse events (thrombocytopenia) when dose adjustment is performed based on LZD plasma concentration | — |
Secondary
| Measure | Time frame |
|---|---|
| Association of LZD plasma concentrations with LZD dose adjustment rate, treatment efficacy, and adverse event occurrence by measuring plasma concentrations | — |
Countries
Japan
Contacts
Public ContactDaiki Yamaguchi
Gifu Prefectural Tajimi Hospital pharmaceutical department
Outcome results
None listed